Proactive Investors - Run By Investors For Investors

ANGLE passes key milestone recruitment is completed for phase III clinical trial of its liquid biopsy system

A total of 400 people will with late-stage breast cancer will be screened using the Parsortix system, which harvests tumour cells
researcher using microscope
Results from the trial will be submitted to the Food & Drug Administration by mid-year as planned

ANGLE PLC (LON:AGL, OTCQX:ANPCY) said it had passed a “key milestone” following the completion of recruitment to a phase III clinical study to assess the potential of its liquid biopsy in metastatic breast cancer.

A total of 400 people will be screened using the Parsortix system, which harvests tumour cells. The work is being carried out at world-leading cancer centres in Texas, California and Illinois.

READ: “Significant milestone” for ANGLE as it kicks off second ovarian cancer study

Results from the trial will be submitted to the Food & Drug Administration by mid-year as planned.

However, ANGLE cautioned that the timeline, once the FDA has received all the data, is uncertain as researchers are following a completely new protocol for an entirely unique product – in other words, the regulator doesn’t have an established blueprint or tick-sheet to follow.

Chief executive Andrew Newland said: “We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer."

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use